solidbio.com - SLDB Income before deduction of interest, taxes and amortization
Solid Biosciences Inc. (SLDB) faces risks due to a rapid cash burn rate and the complexity of gene testing. However, the potential for multi-million dollar therapy pricing upon regulatory approval creates significant value. Demand is supported by the uniqueness of the vectors used to treat Duchenne muscular dystrophy. The current EBITDA_Co level reflects the operational cash flow dynamics, where the current mark is 0.00, allowing for an assessment of the issuer's financial stability.
Summary analytical data breakdowns for Solid Biosciences (SLDB)
- share price and expert price forecast:
- issuer market value details:
- book capitalization information:
- business debt structure and liquidity details:
Debt to Capital Solid Biosciences Inc.|SLDB - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Solid Biosciences Inc|SLDB - Company Aggregate Debts|Debt to Book Value Solid Biosciences|SLDB - Company Long-Term Debts|Short-Term Debt Volume Solid Biosciences|Immediate Liquidity solidbio.com
- net income and valuation multiples indicators:
SLDB - Company Net Income|Net Profit Forecast Solid Biosciences Inc.|SLDB - P/E Multiple|Projected Price to Earnings solidbio.com|SLDB - PEG Multiple|Company Value to EBITDA Solid Biosciences|SLDB - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Solid Biosciences|SLDB - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months solidbio.com|SLDB - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Solid Biosciences Inc.
Summary company analytics:SLDB - Solid Corp
To fundamentally assess the market status of Solid Biosciences Inc. (SLDB), it is critical to track the actual cash efficiency of the business. This indicator measures the daily inflow of operating funds before interest, and an analysis of actual EBITDA allows for the timely detection of stagnation in the gene therapy pipeline when the diversification of gene delivery technology platforms ceases to ensure the company's financial stability.
Who Solid Biosciences Inc. competes with
TEM: Operating profit before amortization|QGEN: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization IONS (ionispharma.com)|RGEN: Operating profit EBITDA|RNA (Avidity Biosciences Inc) - Profit before payment of interest, taxes and amortization|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|GeneDx Corp (WGS) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Ultragenyx Pharmaceutical (RARE)|BEAM - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Sarepta SRPT|Operating income before deduction of amortization Twist Bioscience Inc (TWST)|10x Genomics Corp - Operating profit EBITDA|Intellia Corp (NTLA) - Operating profit before deduction of amortization|STOK: Operating profit EBITDA|BLFS - Operating income before deduction of amortization|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Profit before interest, taxes and amortization Maze Therapeutics, Inc. MAZE|Profit before payment of interest, taxes and amortization Sionna Pharma (SION)|Prime Medicine Bio - Operating profit before amortization|Operating profit EBITDA TSHA (Taysha Gene Therapies)|QURE - Operating profit before deduction of amortization|MeiraGTx - Operating profit EBITDA|Profit before interest, taxes and amortization REGENXBIO Inc|Ocugen Corp (OCGN) - Profit before payment of interest, taxes and amortization|PACB - Operating income before deduction of amortization|Operating profit before deduction of amortization BNTC|DSGN: Income before deduction of interest, taxes and amortization|Operating profit EBITDA RCKT|Operating income before deduction of amortization 4DMT|Profit before payment of interest, taxes and amortization Lexeo Therapeutics, Inc. LXEO|KRRO: Operating profit before amortization|Editas Medicine, Inc. - Operating profit EBITDA|silence-therapeutics.com (SLN) - Operating profit before deduction of amortization|PRQR (proqr.com) - Operating profit before deduction of amortization|CDXS - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Sangamo|Nautilus Biotechnology Inc (NAUT) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Metagenomi, Inc. (MGX)|Profit before payment of interest, taxes and amortization DTIL (precisionbiosciences.com)|Operating profit EBITDA GBIO (Generation Bio)|BOLD: Operating profit before amortization|Exicure Corp - Operating profit EBITDA|IMNN: Profit before payment of interest, taxes and amortization|PHIO: Operating profit EBITDA|Operating profit before amortization MBIO|Profit before payment of interest, taxes and amortization TransCode Therapeutics Inc.|Operating profit before amortization BNGO (Bionano)|Operating profit EBITDA APDN|Operating profit EBITDA bluebird bio, Inc (BLUE)|Profit before payment of interest, taxes and amortization ImmunoPrecise Antibodies Ltd. IPA|Operating income before deduction of amortization omegatherapeutics.com (OMGA)|OMIC - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Regulus Therapeutics, Inc.|Syros (SYRS) - Profit before payment of interest, taxes and amortization|TBIO (Telesis Bio, Inc) - Profit before payment of interest, taxes and amortization|TCON (TRACON Pharmaceuticals) - Operating profit EBITDA|unitybiotechnology.com (UBX) - Operating income before deduction of amortization
